Tag: pdl-1
Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer
1. The overall response rate (ORR) was 25.6%, with 8.0% of the patients achieved complete response. 2. Common treatment-related adverse ...
#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
#VisualAbstract: Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer
1. First line treatment with pembrolizumab-chemotherapy showed significant improvement in progression-free survival compared to chemotherapy alone in patients with metastatic ...